Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study

Japanese Journal of Chemotherapy

Volumn 56, Issue SUPPL. 1, 2008, Pages 63-80

  Saito, Atsushi ^a   Tanigawara, Yusuke ^b   Watanabe, Akira ^c   Aoki, Nobuki ^d   Niki, Yoshihito ^e   Kohno, Shigeru ^f   Kaku, Mitsuo ^g   Hori, Seiji ^h   Totsuka, Kyoichi ⁱ  

^a Japanese Red Cross Nagasaki Genbaku Isahaya Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d Shinrakuen Hospital   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Fluoroquinolone; PK PD; Respiratory tract infection; Sitafloxacin

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; SITAFLOXACIN; TOSUFLOXACIN;

ABNORMAL SENSATION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CELL COUNT; CHLAMYDIASIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; EOSINOPHIL COUNT; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE COUNT; MYCOPLASMA PNEUMONIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; NONHUMAN; OPEN STUDY; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; SECONDARY INFECTION; SIDE EFFECT; STOMACH DISCOMFORT; STOMATITIS; STREPTOCOCCUS PNEUMONIAE; THIRST; VOMITING;

EID: 43449091278     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Japanese source.
2. Japanese source.
3. Ferrara A M: New fluoroquinolones in lower respiratory tract infections and emerging patterns of Pneumococcal resistance. Infection 2005; 33:106-14
4. Japanese source.
5. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y: Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992; 36: 1491-8
6. Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K: Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother 2000; 6: 131-9
7. Akasaka T, Onodera Y, Tanaka M, Sato K: Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 1999; 43:530-6
8. Andes D R, Craig W A: In vivo pharmacodynamic activity of sitafloxacin (SIT) against multiple bacterial pathogens [Abstract]. Program and abstracts from the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, CA
9. Craig W A: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
10. Japanese source.
11. Japanese source.
12. Japanese source.
13. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 7th ed. Approved Standard MT-A7. Wayne, PA: CLSI; 2006
14. Japanese source.
15. Kawamura-Sato K, Hasegawa T, Torii K, Ito H, Ohta M: Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Current Microbiol 2005; 51: 27-30
16. Davies T A, Yee Y C, Goldschmidt R, Bush K, Sahm D F: Evangelista A: Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 2006; 57: 437-42
17. Japanese source.
18. Japanese source.
19. Japanese source.
20. Japanese source.
21. Craig W A: Does the dose matter? Clin Infect Dis 2001; 33: S233-7